EUCTR2007-006084-73-DE进行中（未招募）不适用
An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAjectTM in Subjects with Type 1 Diabetes Mellitus
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- BIODEL Inc
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Completed the VIAjectTM-06J protocol
- •2. Informed consent must be obtained in writing for all subjects
- •3. No deterioration of the initial status on VIAjectTM as judged by the investigator
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. History of frequent severe hypoglycemia within the prior six month which prevent study participation at the discretion of the Investigator
- •2. History of known hypersensitivity to any of the components in the study medication
- •3. Progressive disease likely to prove fatal
- •4. Known significant hepatic disease or serum AST values >3 upper limit of normal or bilirubin levels >1.5 upper limit of normal
- •5. Severe complications of diabetes mellitus including a history or findings of Stage III or IV diabetic retinopathy, proteinuria >2+ by urine dipstick, serum creatinine of >1.8 mg/dL for males or >1.5 mg/dL for females , history of renal transplant, severe peripheral vascular disease, which has resulted in amputation or recent onset of chronic foot ulcers or claudication, or the recent, clinically documented loss a pedal pulse
- •6. History of moderate to severe ketoacidosis within the last 3 month preceding screening for the study
- •7. Current drug or alcohol abuse, or a history which in the opinion of the Investigator will impair subject safety or protocol compliance
- •8. Current significant cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric and/or hematological disease as evaluated by the Investigator
- •9. A sexually active woman of childbearing age not actively and consistently practicing birth control by using a medically accepted device or therapy or a woman intending to become pregnant during the study
- •10. Abnormal ECG, safety lab or physical examination results which, in the opinion of the Investigator, render the participation of the subject in the study to be inappropriate or unsafe
- •11. A history of lack of compliance with medical instructions, recent drug or alcohol abuse, or other reasons which, in the opinion of the Investigator, render the participation of the subject in the study to be inappropriate and unsafe
研究者
相似试验
进行中（未招募）
不适用
An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects with Type 2Diabetes MellitusDiabetes Mellitus Type 2MedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2007-006085-15-DEBiodel Inc.400
进行中（未招募）
1 期
OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004MedDRA version: 20.0Level: HLTClassification code 10034005Term: Parkinson's disease and parkinsonismSystem Organ Class: 100000004852EUCTR2015-003513-24-DEIntec Pharma, Ltd.266
进行中（未招募）
1 期
OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004MedDRA version: 20.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 100000004852EUCTR2015-003513-24-SKIntec Pharma, Ltd.266
进行中（未招募）
1 期
OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004MedDRA version: 20.0 Level: HLT Classification code 10034005 Term: Parkinson's disease and parkinsonism System Organ Class: 100000004852EUCTR2015-003513-24-GBIntec Pharma, Ltd.266
进行中（未招募）
1 期
OPEN-LABEL EXTENSION and FOLLOW-UP of STUDY IN 11 004MedDRA version: 20.0Level: HLTClassification code 10034005Term: Parkinson's disease and parkinsonismSystem Organ Class: 100000004852Parkinson's DiseaseEUCTR2015-003513-24-ITINTEC PHARMA LTD266